- Posts: 19
- Thank you received: 1
1. You must be a registered website user in order to post and comment. Guests may read only.
2. Be kind and helpful, not rude and cynical.
3. Don't advertise or promote anything. You will be banned from the group.
4. Report problems to the moderators. THANK YOU!
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000942/WC500039537.pdf
Increased bone marrow reticulin
Increased bone marrow reticulin is believed to be a result of TPO receptor stimulation, leading to an
increased number of megakaryocytes in the bone marrow, which may subsequently release cytokines.
Increased reticulin may be suggested by morphological changes in the peripheral blood cells and can
be detected through bone marrow biopsy. Therefore, examinations for cellular morphological
abnormalities using peripheral blood smear and complete blood count (CBC) prior to and during
treatment with romiplostim are recommended. See section 4.8 for information on the increases of
reticulin observed in romiplostim clinical trials.
If a loss of efficacy and abnormal peripheral blood smear is observed in patients, administration of
romiplostim should be discontinued, a physical examination should be performed, and a bone marrow
biopsy with appropriate staining for reticulin should be considered. If available, comparison to a prior
bone marrow biopsy should be made. If efficacy is maintained and abnormal peripheral blood smear is
observed in patients, the physician should follow appropriate clinical judgment, including
consideration of a bone marrow biopsy, and the risk-benefit of romiplostim and alternative ITP
treatment options should be re-assessed.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.

Platelet Disorder Support Association
8751 Brecksville Road Suite 150
Cleveland, OH 44141
440.746.9003 | pdsa@pdsa.org
The Platelet Disorder Support Association is a 501(c)3 organization and donations are tax deductible to the fullest extent allowed by law.
© Copyright 1997 - 2026, Platelet Disorder Support Association. All rights reserved.
IMPORTANT!
The Platelet Disorder Support Association does not provide medical advice or endorse any medication, vitamins or herbs. The information contained herein is not intended nor implied to be a substitute for professional medical advice and is provided for educational purposes only. Always seek the advice of your physician or other qualified healthcare provider before starting any new treatment, discontinuing an existing treatment and to discuss any questions you may have regarding your unique medical condition.